Advertisement

Search Results

Advertisement



Your search for Hagop Kantarjian, MD,Hagop Kantarjian, MD matches 59 pages

Showing 51 - 59


issues in oncology
cost of care

In Search of ‘Just’ Prices: Questioning the High Cost of New Cancer Drugs

As the oncology community begins the slow and often difficult-to-define transition from volume to value in the delivery of cancer care, the relationship between the price and value of certain high-priced cancer drugs is getting more scrutiny. We generally correlate the efficacy of a new drug and...

leukemia

A Lasting Legacy

When Emil J Freireich, MD, retires from the University of Texas MD Anderson Cancer Center on September 1, he will have spent 50 years at the institution and a total of 60 years in the pursuit of curing childhood leukemia as well as other cancers and in the educational development of young...

cost of care
hematologic malignancies

Study Shows Current Blood Cancer Drug Prices Are Not Justified

The costs associated with cancer drug prices have risen dramatically over the past 15 years, a trend concerning to many oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic cancers are...

cost of care

Making Their Voices Heard: 118 Oncologists Speak Out About Stemming the High Cost of Cancer Drugs

In a bold move to shed light on the ramifications of the ever-increasing cost of cancer drugs for patients with cancer and for the health-care system, 118 prominent oncologists came together to write a commentary in Mayo Clinic Proceedings detailing their concerns.1 To learn more about these...

issues in oncology

Is Health Care in the United States a Basic Human Right or an Entitlement?

Mercy Killers is a one-man show that details the consequences of a medical health-care catastrophe (breast cancer) in a family.1 This disturbing fictional account is actually a daily event in cancer centers: losing insurance for technicalities, losing a home because of an inability to pay the...

leukemia

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).

health-care policy
hematologic malignancies
leukemia
issues in oncology
issues in oncology
cost of care

Study Finds Current Prices of Hematologic Cancer Drugs Are Not Justified

The costs associated with cancer drug prices have risen dramatically over the past 15 years, a trend concerning to many oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded that the majority of existing treatments for hematologic cancers are...

issues in oncology
issues in oncology
issues in oncology
cost of care

Experts Explore the Reasons Behind the High Cost of Cancer Drugs in America

Increasingly high prices for cancer drugs are affecting patient care, as well as the health-care system overall, in the United States. These findings were published in a special article by Rajkumar and Kantarjian in the journal Mayo Clinic Proceedings. “Americans with cancer pay 50% to 100%...

leukemia

‘Faster and Deeper Responses’ With Dasatinib vs Imatinib in Chronic-Phase CML Patients

Dasatinib (Sprycel) resulted in “faster and deeper responses” compared to imatinib (Gleevec) among patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML), according to a 3-year follow-up of the randomized phase III DASISION (Dasatinib vs Imatinib Safety In...

Advertisement

Advertisement



Advertisement